Back to Search

A Phase 2/3, Randomized, Double Blind, Placebo-controlled, Multicenter Study of NKTR-255 vs Placebo Following CD19-directed CAR-T Cell Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma


  • Protocol Number: 202303006
  • Principal Investigator: Dipersio, John
  • Cancer Types: Gene & Cellular Immunotherapy, Lymphoma

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions